NCT02292459撤回3 期
A Multicenter, Open Label, Non-controlled Phase 3 Clinical Trial of the Efficacy and the Safety for the Relief of Constipation of Polyethylene Glycol 3350
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- Bayer
- 主要终点
- Number of bowel movements per week
研究概览
简要总结
The purpose of this study is to evaluate the complete resolution of constipation in participants taking PEG 3350 compared to those taking PEG 4000, based on analysis of the number of bowel movements from self-reported bowel movement (BM) data. The complete resolution of constipation is defined as the elimination of straining or of hard/lumpy stools.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •meets diagnostic criteria for functional constipation. This includes loose stools that are rarely present without the use of laxatives and 2 or more of the following: straining during at least 25% of defecations; lumpy or hard stools in at least 25% of defecations; sensation of incomplete evacuation for at least 25% of defecations; sensation of anorectal obstruction/blockage for at least 25% of defecations; manual maneuvers to facilitate at least 25% of defecations [e.g., digital evacuation, support of the pelvic floor]; and fewer than 3 defecations per week. Criteria for functional constipation must be fulfilled for last 3 months, with symptom onset at least 6 months prior to diagnosis.
- •willing to use study drug for up to 7 days as directed, and must agree to record bowel movements (frequency, consistency, etc.) accurately and consistently in a daily diary, and make 3 clinic visits.
- •except for constipation, must be otherwise in good health, as determined by physical exam and medical history.
- •agrees not to use any other products (drug, herbal, dietary supplements including fiber, etc.) to treat their constipation during the course of the study.
- •agrees not to use any medication known to cause constipation during the course of the study.
- •agree to maintain a similar diet from the week prior to randomization through the end of the study.
- •females must be either surgically sterile, 2 years post-menopausal, or attest that they are using an acceptable method of contraception (including hormonal birth control, intrauterine device [IUD], double barrier methods, or vasectomized partner).
- •females of childbearing potential must have urine pregnancy test (human chorionic gonadotropin [HCG]) that is negative at Baseline.
- •must be able to read the diaries in Russian.
排除标准
- •currently under a doctor's care and treatment for constipation.
- •have current constipation episode for more than one week prior to randomization.
- •history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.).
- •history of more than 3 months of constipation in the past year.
- •have severe abdominal pain as the predominant constipation symptom.
- •had with bowel movement in 48 hours prior to randomization.
- •have celiac disease or known gluten sensitivity.
- •history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy.
- •have known renal or hepatic insufficiency.
- •have gastrointestinal bleeding or acute infection.
- •history of alcohol or drug abuse.
- •history of psychiatric disorders.
- •history of significant ongoing medical problems, including kidney disease, or are scheduled for surgical procedures.
- •currently taking or have taken within 7 days of randomization a concomitant medication that causes constipation, including opiates, antidepressants, selective serotonin reuptake inhibitors (SSRIs), antimotility agents, and anticholinergics, etc.
- •plan to use laxatives during the treatment period other than the study medication.
- •have participated in an investigational clinical, surgical, drug or device study within the past 30 days. (Concurrent skin patch testing of cosmetic or suncare products is allowed.)
- •pregnant or lactating.
- •allergic to polyethylene glycol or maltodextrin.
- •employed or have immediate family members employed by a company that manufactures laxative products.
研究组 & 干预措施
PEG 3350
Experimental
Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.
干预措施: Polyethylene Glycol 3350 Powder for Solution (PEG 3350) (Drug)
PEG 4000
Active Comparator
Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.
干预措施: Polyethylene Glycol 4000 Powder for Solution (PEG 4000) (Drug)
结局指标
主要结局
Number of bowel movements per week
时间窗: Up to 7 days after start of treatment
次要结局
- Time to first bowel movement(Up to 7 days after start of treatment)
- Number of participants who experience changes in straining and hard or lumpy stools(Up to 7 days after start of treatment)
- Number of participants who experience changes in stool consistency(Up to 7 days after start of treatment)
- Number of participants who experience changes in the sensation of stool evacuation(Up to 7 days after start of treatment)
研究者
相似试验
已完成
3 期
Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular ProceduresAnesthesia, DentalNCT00309361Novalar Pharmaceuticals, Inc.240
招募中
3 期
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal CancerColon or Upper Rectum AdenocarcinomaNCT06197425Centre Hospitalier Universitaire Dijon1,660
已完成
3 期
Eltrombopag Phase III Study In Chinese Chronic ITP PatientsPurpura, Thrombocytopenic, Idiopathic and Hepatitis CNCT01762761Novartis Pharmaceuticals155
进行中（未招募）
不适用
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan.Prophylaxis against Neisseria meningitidis serogroups A, C, W135 and YEUCTR2014-004973-17-Outside-EU/EEAovartis Vaccines and Diagnostics340
已完成
3 期
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic ArthritisArthritis, PsoriaticNCT01009086Janssen Research & Development, LLC615